EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia

Cameron J Hunter iD, Annie P Im, Rory M Shallis

Cancers · 16.01.2026 · 18 (2) · 275

DOI: 10.3390/cancers18020275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.01.2026. Verfasst von Cameron J Hunter und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Malignant Hematology and Medical Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in TP53 inhibit p53 protective behaviors including cell cycle arrest, DNA damage repair protein recruitment, and apoptosis. The ubiquity of p53 in genome-stabilizing functions leads to an aberrant tumor microenvironment in TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Profound immunosuppression mediated by myeloid-derived suppressor cells, the upregulation of cytokines and cell-surface receptors on leukemic cells, the suppression of native immune regulator cells, and metabolic aberrations in the bone marrow are features of the TP53-mutated AML/MDS marrow microenvironment. These localized changes in the bone marrow microenvironment (BMME) explain why traditional therapies for MDS/AML, including chemotherapeutics and hypomethylating agents, are not as effective in TP53-mutated myeloid neoplasms and demonstrate the dire need for new treatments in this patient population. The unique pathophysiology of TP53-mutated disease also provides new therapeutic approaches which are being studied, including intracellular targets (MDM2, p53), cell-surface protein biologics (immune checkpoint inhibitors, BiTE therapy, and antibody–drug conjugates), cell therapies (CAR-T, NK-cell), signal transduction pathways (Hedgehog, Wnt, NF-κB, CCRL2, and HIF-1α), and co-opted biologic pathways (cholesterol synthesis and glycolysis). In this review, we will discuss the pathophysiologic anomalies of the tumor microenvironment in TP53-mutant MDS/AML, the hypothesized mechanisms of chemoresistance it imparts, and how novel therapies are leveraging diverse therapeutic targets to address this critical area of need.

Schlagwörter

Stichwörter der Autor:innen

TP53acute myeloid leukemiabone marrow microenvironmentchemoresistanceimmunosuppressionmyelodysplastic syndrome

Autor:innen und Institutionen

  • Division of Malignant Hematology and Medical Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.

ORCID-Profile: Cameron J Hunter

Zitieren

APA

Hunter, C. J., Im, A. P., & Shallis, R. M. (2026). Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia. Cancers, 18(2), 275. https://doi.org/10.3390/cancers18020275

Vancouver

Hunter CJ, Im AP, Shallis RM. Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia. Cancers. 2026;18(2):275. doi:10.3390/cancers18020275

BibTeX
@article{Hunter2026,
  author = {Hunter, Cameron J and Im, Annie P and Shallis, Rory M},
  title = {Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {2},
  pages = {275},
  doi = {10.3390/cancers18020275}
}
Kostenlos starten →